329 related articles for article (PubMed ID: 9922382)
1. Pathophysiology of gene-targeted mouse models for cystic fibrosis.
Grubb BR; Boucher RC
Physiol Rev; 1999 Jan; 79(1 Suppl):S193-214. PubMed ID: 9922382
[TBL] [Abstract][Full Text] [Related]
2. Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis.
Grubb BR; Gabriel SE
Am J Physiol; 1997 Aug; 273(2 Pt 1):G258-66. PubMed ID: 9277402
[TBL] [Abstract][Full Text] [Related]
3. Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology.
Olivier AK; Gibson-Corley KN; Meyerholz DK
Am J Physiol Gastrointest Liver Physiol; 2015 Mar; 308(6):G459-71. PubMed ID: 25591863
[TBL] [Abstract][Full Text] [Related]
4. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis.
Jiang Q; Engelhardt JF
Eur J Hum Genet; 1998 Jan; 6(1):12-31. PubMed ID: 9781011
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from the cystic fibrosis pig.
Meyerholz DK
Theriogenology; 2016 Jul; 86(1):427-32. PubMed ID: 27142487
[TBL] [Abstract][Full Text] [Related]
6. Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.
Tang Y; Yan Z; Engelhardt JF
Hum Gene Ther; 2020 May; 31(9-10):524-537. PubMed ID: 32138545
[TBL] [Abstract][Full Text] [Related]
7. Phenotypes of CF rabbits generated by CRISPR/Cas9-mediated disruption of the CFTR gene.
Xu J; Livraghi-Butrico A; Hou X; Rajagopalan C; Zhang J; Song J; Jiang H; Wei HG; Wang H; Bouhamdan M; Ruan J; Yang D; Qiu Y; Xie Y; Barrett R; McClellan S; Mou H; Wu Q; Chen X; Rogers TD; Wilkinson KJ; Gilmore RC; Esther CR; Zaman K; Liang X; Sobolic M; Hazlett L; Zhang K; Frizzell RA; Gentzsch M; O'Neal WK; Grubb BR; Chen YE; Boucher RC; Sun F
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33232302
[TBL] [Abstract][Full Text] [Related]
8. Small intestinal glucose absorption in cystic fibrosis: a study in human and transgenic DeltaF508 cystic fibrosis mouse tissues.
Hardcastle J; Harwood MD; Taylor CJ
J Pharm Pharmacol; 2004 Mar; 56(3):329-38. PubMed ID: 15025858
[TBL] [Abstract][Full Text] [Related]
9. Abnormal enamel development in a cystic fibrosis transgenic mouse model.
Wright JT; Kiefer CL; Hall KI; Grubb BR
J Dent Res; 1996 Apr; 75(4):966-73. PubMed ID: 8708137
[TBL] [Abstract][Full Text] [Related]
10. Loss of cftr function leads to pancreatic destruction in larval zebrafish.
Navis A; Bagnat M
Dev Biol; 2015 Mar; 399(2):237-48. PubMed ID: 25592226
[TBL] [Abstract][Full Text] [Related]
11. Vector-specific complementation profiles of two independent primary defects in cystic fibrosis airways.
Zhang Y; Jiang Q; Dudus L; Yankaskas JR; Engelhardt JF
Hum Gene Ther; 1998 Mar; 9(5):635-48. PubMed ID: 9551612
[TBL] [Abstract][Full Text] [Related]
12. Mouse models of cystic fibrosis: phenotypic analysis and research applications.
Wilke M; Buijs-Offerman RM; Aarbiou J; Colledge WH; Sheppard DN; Touqui L; Bot A; Jorna H; de Jonge HR; Scholte BJ
J Cyst Fibros; 2011 Jun; 10 Suppl 2():S152-71. PubMed ID: 21658634
[TBL] [Abstract][Full Text] [Related]
13. Physiological basis of cystic fibrosis: a historical perspective.
Quinton PM
Physiol Rev; 1999 Jan; 79(1 Suppl):S3-S22. PubMed ID: 9922374
[TBL] [Abstract][Full Text] [Related]
14. Cystic fibrosis: a disease of vulnerability to airway surface dehydration.
Boucher RC
Trends Mol Med; 2007 Jun; 13(6):231-40. PubMed ID: 17524805
[TBL] [Abstract][Full Text] [Related]
15. Nasal abnormalities in cystic fibrosis mice independent of infection and inflammation.
Hilliard TN; Zhu J; Farley R; Escudero-Garcia S; Wainwright BJ; Jeffery PK; Griesenbach U; Bush A; Davies JC; Alton EW
Am J Respir Cell Mol Biol; 2008 Jul; 39(1):19-25. PubMed ID: 18239192
[TBL] [Abstract][Full Text] [Related]
16. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
17. Rationale for hypertonic saline therapy for cystic fibrosis lung disease.
Tarran R; Donaldson S; Boucher RC
Semin Respir Crit Care Med; 2007 Jun; 28(3):295-302. PubMed ID: 17562499
[TBL] [Abstract][Full Text] [Related]
18. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease.
Zhou Z; Duerr J; Johannesson B; Schubert SC; Treis D; Harm M; Graeber SY; Dalpke A; Schultz C; Mall MA
J Cyst Fibros; 2011 Jun; 10 Suppl 2():S172-82. PubMed ID: 21658636
[TBL] [Abstract][Full Text] [Related]
19. Modifier genes in cystic fibrosis lung disease.
Merlo CA; Boyle MP
J Lab Clin Med; 2003 Apr; 141(4):237-41. PubMed ID: 12677168
[TBL] [Abstract][Full Text] [Related]
20. Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models.
Wang Y; Wrennall JA; Cai Z; Li H; Sheppard DN
Int J Biochem Cell Biol; 2014 Jul; 52():47-57. PubMed ID: 24727426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
